In 2012,Yervoyreceived the award, after its initial approval designed for metastatic or unresectable melanoma. Building on this pioneering science, the Company continues to analyze the potential of Immuno-Oncology to extend survival in a few of the hardest-to-treat cancers. We are very happy to become acknowledged for our Business’s scientific contributions to the historic time in cancer research, when the technology of Immuno-Oncology is assisting to change anticipations in cancer care and attention, saidFrancis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb. Getting the Prix Galien USA 2015 Award for Best Biotechnology Product underscores our attempts with theOpdivoearly – and late-stage clinical plan in patients with a number of the hardest-to-deal with cancers, like advanced melanoma and squamous non-small cell lung cancer..James Hospital. ‘The consolidation among physician groups may be the first step in greater consolidation over the Chicago marketplace, as the health care sector could be more aligned with two primary segments: wellness systems and health plans,’ said Cherry. ‘Look for tensions between both of these segments to improve.’ Why Pharmaceutical Companies Need Market Overviews Market Overviews give a detailed analysis of local healthcare marketplace drivers in 87 of the nation’s most powerful metro areas, allowing pharmaceutical executives to quickly gain geographic area expertise. Each record provides local-level insights into: wellness systems and hospitals, doctors, health programs, Medicare/Medicaid, pharmaceutical environment, employers and legislation..